This company has been marked as potentially delisted and may not be actively trading. Acorda Therapeutics (ACOR) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ACOR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Another major healthcare company files Chapter 11 bankruptcyMay 9, 2025 | msn.comAnother major healthcare company files for Chapter 11 bankruptcyMay 3, 2025 | msn.comAcorda: I didn't know Tony Yang was wanted in ChinaOctober 9, 2024 | msn.comMultiple Sclerosis Therapeutic Market to hit USD 38.1 billion by 2032, says Global Market Insights Inc.September 30, 2024 | finance.yahoo.comAcorda amid POGO allegations: I love country, PNPSeptember 25, 2024 | msn.comAcorda: I did not accept money from GuoSeptember 25, 2024 | msn.comIntranasal Drug Delivery Research Report 2024: Global Market to Reach $92.6 Billion by 2030 - Controlled Release Technology is the New Buzz WordSeptember 12, 2024 | uk.finance.yahoo.comMultiple Sclerosis Drugs Market Outlook and Strategic Business Report 2024-2030: Increased Awareness and Diagnosis Rates Boosting Treatment AdoptionAugust 26, 2024 | sg.finance.yahoo.comEssential cancer treatment company files Chapter 11 bankruptcyMay 16, 2024 | msn.comAcorda Therapeutics Announces Delisting from NasdaqApril 15, 2024 | businesswire.comAcorda Therapeutics Inc.April 14, 2024 | wsj.comPearl River-based Acorda Therapeutics to close; 97 jobs impactedApril 8, 2024 | msn.comRiskiest Junk Bonds Shunned in Europe on Rising Risk of DefaultApril 6, 2024 | finance.yahoo.comAcorda Therapeutics Announces Nasdaq Delisting NotificationApril 3, 2024 | businesswire.comAcorda Therapeutics Files for Chapter 11 BankruptcyApril 3, 2024 | baystreet.caCrude Oil Surges Over 1%; US Factory Orders Increase In FebruaryApril 2, 2024 | msn.comWhy Acorda Therapeutics Stock Is Down Nearly 90%April 2, 2024 | benzinga.comAcorda Therapeutics (Nasdaq:ACOR) HeadlineTrading was temporarily halted for "ACOR" at 11:04 AM with a stated reason of "LULD pause."...April 2, 2024 | marketbeat.comAcorda Therapeutics (Nasdaq:ACOR) HeadlineTrading was temporarily halted for "ACOR" at 11:04 AM with a stated reason of "LULD pause."...April 2, 2024 | marketbeat.comAcorda Therapeutics (Nasdaq:ACOR) HeadlineTrading was temporarily halted for "ACOR" at 10:04 AM with a stated reason of "LULD pause."...April 2, 2024 | marketbeat.comAcorda Therapeutics (Nasdaq:ACOR) HeadlineTrading was temporarily halted for "ACOR" at 10:04 AM with a stated reason of "LULD pause."...April 2, 2024 | marketbeat.comAcorda Therapeutics (Nasdaq:ACOR) HeadlineTrading was temporarily halted for "ACOR" at 10:04 AM with a stated reason of "LULD pause."...April 2, 2024 | marketbeat.comWhy Is Acorda Therapeutics (ACOR) Stock Down 72% Today?April 2, 2024 | investorplace.comNorth American Morning Briefing: Stocks Seen Weaker as Doubts Over Fed Cuts MountApril 2, 2024 | morningstar.comMMerz Therapeutics: Merz Enters Asset Purchase Agreement With a US-Based Biotech CompanyApril 2, 2024 | finanznachrichten.deAcorda retires from PNP after 3 months of extended serviceApril 1, 2024 | msn.comRetired PNP chief Acorda: I did my bestApril 1, 2024 | msn.comStocks to Watch: PVH, Canoo, Acorda TherapeuticsApril 1, 2024 | marketwatch.comAcorda Therapeutics shares sink nearly 40% after bankruptcy filingApril 1, 2024 | msn.comAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024April 1, 2024 | finance.yahoo.comAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024March 26, 2024 | finance.yahoo.comKlick Health Launches First AI Social Media Comment Moderator for Life Sciences IndustryMarch 11, 2024 | finance.yahoo.com3 Biotech Stocks to Watch in March for SuccessFebruary 28, 2024 | stocknews.comAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest ReportFebruary 23, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comAcorda: No policy vs. TikTok use in PNPFebruary 20, 2024 | msn.comAcorda: PNP can’t interfere with people’s initiative for Charter changeFebruary 6, 2024 | msn.comTeodoro, Acorda nix Mindanao separation from PhilippinesFebruary 5, 2024 | msn.comPNP chief Acorda tells ranks: Ignore ‘political noise’January 31, 2024 | msn.comDementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - TechnavioJanuary 29, 2024 | finance.yahoo.comAcorda Therapeutics To Regain Worldwide Commercialization Rights To FAMPYRAJanuary 11, 2024 | markets.businessinsider.com3 Biotech Stocks to Keep an Eye on in 2024January 10, 2024 | stocknews.comAcorda files raps vs person spreading false info in viral vlogJanuary 8, 2024 | msn.comAcorda slams vlogger in 'disinformation' driveJanuary 8, 2024 | msn.comAcorda files cybercrime raps vs person spreading false info in a vlogJanuary 8, 2024 | msn.comAcorda eyes Pinoy apps vs cybercrimesJanuary 7, 2024 | msn.comAcorda Therapeutics Inc ACORJanuary 6, 2024 | morningstar.comMAshvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical OperationsJanuary 4, 2024 | finance.yahoo.comModerna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?December 18, 2023 | stocknews.comAcorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The IndustryDecember 18, 2023 | finance.yahoo.com Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address ACOR Media Mentions By Week ACOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACOR News Sentiment▼0.001.08▲Average Medical News Sentiment ACOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACOR Articles This Week▼00▲ACOR Articles Average Week Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today GILD News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today EXEL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACOR) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredIs America’s Everything Bubble About to Burst?On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acorda Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
